On November 18, 2024, Paul Sekhri, President, Chief Executive Officer, and Executive Chairperson of vTv Therapeutics Inc, purchased 5,000 shares of the company. This transaction was documented in a SEC Filing. Following this acquisition, the insider now owns a total of 5,000 shares of vTv Therapeutics Inc.
vTv Therapeutics Inc (VTVT, Financial) is a clinical-stage biopharmaceutical company focused on the discovery and development of orally administered small molecule drug candidates. The company is engaged in the development of treatments for a range of human diseases, including diabetes and inflammatory disorders.
The insider transaction history for vTv Therapeutics Inc indicates that there has been one insider buy in total over the past year, with no insider sells during the same period. This reflects a trend of insider buying activity within the company.
On the day of the recent purchase, shares of vTv Therapeutics Inc were trading at $16.76 each, resulting in a market cap of $42.92 million. The stock's GF Value is estimated at $6.05, giving it a price-to-GF-Value ratio of 2.77. This suggests that the stock is significantly overvalued based on its GF Value.
The GF Value is an intrinsic value estimate developed by GuruFocus, calculated using historical multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow. It also incorporates a GuruFocus adjustment factor based on the company’s past returns and growth, along with future estimates of business performance from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
